The 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European Renal Association Immunonephrology Working Group

Frangou E., Kronbichler A., Steiger S., Bruchfeld A., Caravaca-Fontán F., Mirioglu Ş., ...Daha Fazla

CLINICAL KIDNEY JOURNAL, cilt.19, sa.1, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 19 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1093/ckj/sfaf381
  • Dergi Adı: CLINICAL KIDNEY JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Anahtar Kelimeler: anti-nephrin, immunosuppression, kidney biopsy, nephrotic syndrome, paediatric
  • İstanbul Üniversitesi Adresli: Evet

Özet

Despite advances and therapeutic progress, nephrotic syndrome (NS) in childhood remains challenging due to its heterogeneous presentation, variable response to treatment and the potential of adverse long-term kidney outcomes. The recently published KDIGO 2025 clinical practice guideline for the management of NS in children refines the definitions of relapse, infrequently- and frequently-relapsing NS and steroid-resistant NS. Herein we describe the revised definitions, summarize the key updates of the KDIGO 2025 guidelines and comment on the new treatment algorithm from a European viewpoint, highlighting the need for individualized approaches to minimize toxicity and optimize long-term kidney outcomes in NS in children.